Perimenopause Financial and Insurance Planning: A Complete Guide

Print or save as PDFOpens the printable cost worksheet and your print dialog. No sign-up.

Key numbers

• 10 yearsLongest typical length of perimenopause, the transition before menopauseSource: womenshealth.gov, as cited 2026-11-07
• 7.4 yearsMedian total duration of frequent hot flashes or night sweats in SWAN women with frequent symptomsSource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07
• 82%Higher all-cause outpatient visits over 12 months for women with untreated vasomotor symptoms vs matched controlsSource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07
• 57%More work-loss days over 12 months for women with untreated vasomotor symptoms vs matched controlsSource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07
• 3 monthsLynkuet follow-up liver test timing after the baseline testSource: dailymed.nlm.nih.gov, as cited 2026-11-07

At a glance

• Planning horizon / about 4 years on average, up to 10 [1]
• Frequent hot flashes and night sweats / median total duration 7.4 years [2]
• Most effective symptom treatment / hormone therapy for vasomotor symptoms and GSM [3]
• Nonhormone options / CBT, hypnosis, SSRIs or SNRIs, gabapentin, fezolinetant [4]
• Compounded bioidentical hormones / not FDA-approved [5]
• Veozah monitoring / baseline liver tests, then scheduled tests [6]
• Lynkuet monitoring / baseline and 3-month liver tests [7]

Why is this a multi-year cost question?

Perimenopause is the transition before menopause, not a single diagnosis with one treatment course. It usually begins in the 40s and can last up to 10 years [1]. Menopause is confirmed only after 12 months without a period [8][1].

Symptoms often outlast the transition. SWAN enrolled 3,302 women at seven US sites. Among the 1,449 women with frequent symptoms, the median total duration of frequent hot flashes or night sweats was 7.4 years, and median persistence after the final menstrual period was 4.5 years [2]. Women who first reported frequent symptoms while premenopausal or early perimenopausal had a median total duration of more than 11.8 years, and Black women had the longest median total duration at 10.1 years [2].

Untreated symptoms may carry their own costs. In a US claims study of 252,273 women with untreated vasomotor symptoms (mean age 56) matched to controls, the symptomatic women had 82% higher all-cause outpatient visits and 57% more work-loss days over 12 months [18].

What does FDA approval change?

Hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture [3]. FDA-approved hormonal options include systemic estrogen alone, systemic estrogen plus progestogen, progesterone capsules, conjugated estrogens/bazedoxifene, and low-dose vaginal estrogen [9][10][11][12].

Nonhormone options have different labels and monitoring. FDA-approved nonhormonal drugs for vasomotor symptoms include paroxetine 7.5 mg, fezolinetant and elinzanetant; ospemifene and prasterone vaginal insert are approved for painful intercourse due to menopause [13][6][7][14][15]. The Menopause Society 2023 statement recommends CBT, clinical hypnosis, SSRIs or SNRIs, gabapentin and fezolinetant at Level I. It does not recommend supplements or herbal remedies for vasomotor symptoms [4].

Compounded bioidentical hormones are not FDA-approved. FDA says it has no evidence that they are safe and effective and recommends FDA-approved hormone therapy [5]. ACOG says compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist [16].

Which labels add recurring lab costs?

The Veozah label calls for baseline liver tests, then monthly tests for the first three months, then tests at months 6 and 9. It says not to start Veozah if ALT or AST is 2 times the upper limit of normal or more, or total bilirubin is 2 times the upper limit of normal or more [6]. The Lynkuet label calls for baseline liver tests and a follow-up at 3 months [7]. Estrogen labels advise monitoring thyroid function in women on thyroid replacement therapy [17].

What is not set by the diagnosis?

This page does not cover plan-specific rules such as copays, formularies, billing codes, FSA/HSA accounts, Medicare or state mandates, which vary by plan and program. What the menopause evidence does show is a transition that can last up to 10 years [1], symptoms that often persist for years [2], and treatments with different approval status and monitoring requirements [6][7][5].

Check what you know

5 quick questions. Pick an answer to see what this article says.

1. According to the article, how long without a period confirms that menopause has occurred?

6 months24 months12 months

2. In the SWAN study, what was the median total duration of frequent hot flashes or night sweats?

7.4 yearsUnder 2 years4.5 years

3. According to the Veozah label, when are liver tests scheduled after the baseline test?

Only if symptoms returnOnce a year, with no baseline testMonthly for the first three months, then at months 6 and 9

4. According to the article, are compounded bioidentical hormones FDA-approved?

No, they are not FDA-approvedYes, all of them are FDA-approvedOnly the vaginal forms are FDA-approved

5. Which of these does the Menopause Society 2023 statement recommend at Level I?

SupplementsHerbal remediesClinical hypnosis

Score: 0 right, 0 of 5 answered

What people on Reddit report

Reddit posts and replies from r/Menopause about how insurance coverage and out-of-pocket payment shaped the hormone therapy people were offered or chose.

SpinachInside5352 · Menopause

Yeah, they didn't start with that, but insurance would not cover Climara Pro or Activella.

Reports that insurance would not cover two hormone prescriptions a doctor first chose, so the plan had to change.

Read the source discussion

Kiwiatx · Menopause

They did not take insurance so I paid out of pocket.

Reports paying fully out of pocket at a provider that did not accept insurance, then using insurance after a gynecologist took over prescriptions.

Read the source discussion

Ok_Landscape2427 · Menopause

My gyn ended up being very peri/menopause fluent, prescribed HRT on the spot, insurance covered it, there was no story.

Reports that insurance covered hormone therapy without any difficulty once a gynecologist with menopause experience prescribed it.

Read the source discussion

lrondberg · Menopause

I believe that most insurance does cover estradiol and progesterone for women in menopause. Perimenopause may be a different story because there isn't much research on it.

Says generic estradiol and progesterone are usually covered, but perimenopause coverage may differ because there is less research on it.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

Which of my hormone prescriptions does my plan cover, and is there a generic option?If my plan will not cover a brand name, can you prescribe the generic version?What will my total yearly cost be for the visits, medicines and labs you recommend?Which lab tests does this medicine require, and how often will I need them?Does my plan need prior authorization before I can start this medicine?Is a compounded hormone a lower-cost option, and is it FDA-approved?

Copy questions

Frequently asked questions

›What are the main billable items in perimenopause?

They are the specific drug, visit or lab test. Treatment labels differ in the monitoring they call for, such as scheduled liver tests with Veozah and Lynkuet, and those items belong in a multi-year cost estimate [6][7].

›Does perimenopause last long enough to affect a multi-year budget?

Yes. It lasts about four years on average and can last up to 10 years [1]. Frequent hot flashes and night sweats lasted longer in SWAN, with a median of 7.4 years [2].

›Are compounded bioidentical hormones FDA-approved?

No. FDA says it has no evidence that they are safe and effective and recommends FDA-approved therapy [5]. ACOG says they should not be prescribed routinely when FDA-approved formulations exist [16].

References

1. Menopause basics | Office on Women's Health. Menopause basics | Office on Women's Health
2. Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-9. Duration of menopausal vasomotor symptoms over the menopause transition
3. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. The 2022 hormone therapy position statement of The North American Menopause Society
4. New Collective Author. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. The 2023 nonhormone therapy position statement of The North American Menopause Society
5. Menopause | FDA. Menopause | FDA
6. U.S. National Library of Medicine, DailyMed. Veozah fezolinetant prescribing information. Veozah fezolinetant label
7. U.S. National Library of Medicine, DailyMed. Lynkuet elinzanetant prescribing information. Lynkuet elinzanetant label
8. Menopause | Menopause Symptoms | MedlinePlus. Menopause | Menopause Symptoms | MedlinePlus
9. U.S. National Library of Medicine, DailyMed. Premarin oral tablets (still older boxed warning) (estrogens, conjugated) prescribing information. Premarin oral tablets (still older boxed warning) (estrogens, conjugated) label
10. U.S. National Library of Medicine, DailyMed. Duavee (conjugated estrogens/bazedoxifene) prescribing information. Duavee (conjugated estrogens/bazedoxifene) label
11. U.S. National Library of Medicine, DailyMed. Prometrium progesterone capsules prescribing information. Prometrium progesterone capsules label
12. U.S. National Library of Medicine, DailyMed. Estring estradiol vaginal ring prescribing information. Estring estradiol vaginal ring label
13. U.S. National Library of Medicine, DailyMed. Brisdelle paroxetine 7.5 mg prescribing information. Brisdelle paroxetine 7.5 mg label
14. U.S. National Library of Medicine, DailyMed. Osphena ospemifene prescribing information. Osphena ospemifene label
15. U.S. National Library of Medicine, DailyMed. Intrarosa prasterone prescribing information. Intrarosa prasterone label
16. American College of Obstetricians and Gynecologists' Committee on Clinical Consensus-Gynecology. Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6. Obstet Gynecol. 2023;142(5):1266-1273. Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6
17. U.S. National Library of Medicine, DailyMed. Divigel estradiol gel (revised boxed warning) prescribing information. Divigel estradiol gel (revised boxed warning) label
18. Sarrel P, Portman D, Lefebvre P, Lafeuille MH, Grittner AM, Fortier J, et al. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause. 2015. Incremental direct and indirect costs of untreated vasomotor symptoms
19. Reddit participants. Prescribed Junel in perimenopause when I went in for HRT (r/Menopause). Accessed 2026-11-11.
20. Reddit participants. [deleted by user] (r/Menopause). Accessed 2026-11-11.